On target? The challenge of integrating biomarker research in drug development. Interview with Walter Carney.
In spite of the current explosion of interest in biomarker research, industry seems to be struggling to incorporate these advances into drug development and healthcare delivery. Biomarkers in Medicine explored the issues with Dr Walter Carney, a pioneer in linking diagnostics with medicines to target therapies to stratified patient groups. Dr Carney and his colleagues were the first to discover the circulating human epidermal growth factor receptor (HER)2/neu oncoprotein in women with metastatic breast cancer. He has been granted numerous patents pertaining to the HER2/neu and ras oncoproteins, as well as having published extensively in this area. Dr Carney joined the DuPont Medical Products Department in 1982 where he held a variety of management positions in the Diagnostics Division. He was Vice President and General Manager of the Diagnostics and Research Products Division and in 1997 was appointed President of Oncogene Science. Dr Carney also held the position of Vice President of Proprietary Drug Development Programs for OSI Pharmaceuticals until Oncogene Science joined Bayer Diagnostics in late 1999. As part of Bayer HealthCare, Dr Carney continued as Head of the Oncogene Science business, which is a Center of Excellence for Oncology and is focused on the use of novel biomarker tests in linking diagnostics with pharmaceuticals. Oncogene Science is now part of the Global Siemens Medical Solutions Diagnostics, which is the first integrated diagnostics company and driving medical innovation by combining circulating biomarkers with imaging biomarkers.